Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | EIS-12656 |
| Synonyms | |
| Therapy Description |
EIS-12656 inhibits CHD1L (ALC1), which potentially results in decreased PARP-mediated DNA damage repair and tumor cell apoptosis (PMID: 39096699, NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| EIS-12656 | EIS12656|EIS 12656 | EIS-12656 inhibits CHD1L (ALC1), which potentially results in decreased PARP-mediated DNA damage repair and tumor cell apoptosis (PMID: 39096699, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06525298 | Phase Ib/II | EIS-12656 EIS-12656 + Olaparib EIS-12656 + Trastuzumab deruxtecan | EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors | Recruiting | USA | 0 |